Formation Bio is an AI-native drug development company building a clinical-stage pipeline through in-licensing and asset acquisition, with a focus on using technology and AI to accelerate clinical trial execution. In early 2026, the company launched a new subsidiary, Kenmare Bio, to develop a miR-124 inhibitor licensed from a Chinese partner for inflammatory diseases.
None publicly disclosed; private AI-native drug developer focused on in-licensing and clinical development.
FHND5032 IND-enabling studies and Phase 1 entry
Additional pipeline asset in-licensing announcements
Formation Bio has hired former Biogen and Pfizer executives to tackle what it calls R&D's 'boring middle' — the operational bottlenecks between discovery and late-stage development.
Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67.
A first-of-its-kind collaboration to build AI-powered software and custom applications, aiming to bring new medicines to patients more efficiently by leveraging OpenAI's technology and Formation Bio's clinical platform.